Clinicians weigh in on parents hiding GLP-1 use from their children

A recent segment on family health looked at a question more households are facing as GLP-1 medications become common: what happens when parents take drugs like Ozempic or Wegovy but don't tell their children. According to a recent study cited in the segment, about half of parents taking GLP-1 weight-loss drugs are talking openly with their children about the medication ^[1]. That leaves roughly half who are not, according to the same reporting ^[1].

Clinicians quoted in the piece say secrecy around GLP-1 use can contribute to shame and stigma, both about the medication itself and about weight in general ^[1]. The concern isn't abstract. Many adults who struggle with food or body image today point back to parents who dieted secretly or openly in front of them during childhood, according to the segment ^[1]. The worry is that hiding a GLP-1 prescription could repeat that pattern for a new generation, even though the medication itself is different from the diets those adults remember.

Parents who are talking to their kids about GLP-1 use are largely motivated by concern over how visible changes to their bodies or eating habits might affect their children, the segment reports ^[1]. That suggests disclosure decisions are less about the drug and more about managing how children interpret changes they can already see.

Experts in the piece offer some specific suggestions for parents who do choose to talk with their children. They recommend emphasizing health-promoting behaviors, such as getting enough sleep and staying physically active, rather than focusing on a number on the scale ^[1]. They also suggest that parents taking these medications try to model eating regularly and enjoying a variety of foods, rather than restricting or skipping meals in ways children might notice and imitate ^[1]. Eating meals together as a family, when possible, was also cited as beneficial ^[1].

It's worth noting what this story is and isn't. It reflects expert opinion and commentary from clinicians, not a new clinical trial or peer-reviewed research on outcomes ^[1]. The underlying figure — that half of parents disclose GLP-1 use to children — comes from a study referenced in the segment, but the segment itself does not name the study, its size, or where it was published ^[1]. That makes it hard to know how representative the 50 percent figure is of GLP-1 users nationally.

Why it matters for patients

For the growing number of American adults on semaglutide or tirzepatide who are also parents, this raises a practical, everyday question that has nothing to do with dosing or side effects: what to say, if anything, to kids at home. The clinicians quoted argue that the choice to disclose or conceal treatment can shape how children think about both medication and body image later in life ^[1]. That's a values-and-communication issue, not a medical one, and the sources here do not offer a single right answer — only observations about what secrecy might model and what alternative framing might look like ^[1].

Because GLP-1 use has become common enough to affect a large share of households, this kind of family conversation is now a routine part of living with the medication for many people, not a rare edge case ^[1]. The segment frames this as an emerging, practical concern tied to how fast these drugs have spread, rather than a settled clinical guideline ^[1].

What happens next

The sources reviewed here do not describe any planned research, guidelines, or follow-up reporting on this specific topic. It is not yet known whether professional pediatric or obesity-medicine groups plan to issue formal guidance on parent-child disclosure of GLP-1 treatment.